MASH: The Silent Liver Crisis Linked to Obesity and Diabetes

Metabolic dysfunction-associated steatohepatitis, or MASH, is a liver disease closely tied to obesity, Type 2 diabetes, and high cholesterol. The condition causes inflammation and scarring in the liver, disrupting how the body handles fats and sugars. In Germany alone, around 4% of the general population has MASH, with rates rising to 15–50% among those with metabolic syndrome.

MASH develops primarily due to obesity, which triggers liver damage over time. Without treatment, it can lead to serious complications, including hypertension, polycystic ovary syndrome (PCOS), heart disease, sleep apnea, and even obesity-related cancers. By 2030, the Global Liver Institute estimates that up to 357 million people worldwide may suffer from fatty liver diseases, including advanced MASH.

Managing the condition often starts with lifestyle changes. A Mediterranean diet—rich in lean protein, fish, fruits, vegetables, whole grains, and nuts—helps improve liver function and metabolic health. Regular exercise, such as brisk walking or high-intensity interval training, also plays a key role in slowing disease progression.

For those with severe obesity, bariatric surgery can be life-changing. Studies show it extends lifespan and reduces the need for liver transplants in advanced cases. Medications like Resmetiron (Rezdiffra) and Semaglutide (Wegovy™) have also proven effective in reversing liver damage and improving overall metabolism.

Beyond weight control, keeping blood sugar, blood pressure, and cholesterol in check remains critical. These steps help prevent further liver damage and lower the risk of related diseases.

Treatment for MASH combines diet, exercise, medication, and sometimes surgery. Each approach targets the root causes—obesity, poor metabolism, and inflammation—to protect liver function. With rising global cases, early intervention and consistent management are becoming more important than ever.